Equities

PetIQ Inc

PetIQ Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)30.76
  • Today's Change-0.02 / -0.06%
  • Shares traded1.88m
  • 1 Year change+61.98%
  • Beta1.7349
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PetIQ, Inc. is a pet medication and wellness company, which provides veterinary products and services. The Company operates through two segments: Products and Services. Products segment manufactures and distributes pet medication and health and wellness products to major United States retail and e-commerce channels through more than 60,000 points of distribution. It is focused its offerings on value-branded products, and third-party branded products for dogs and cats, including pet Rx medications, OTC medications, and wellness products. Services segment provides a comprehensive suite of services at approximately 2,600 community clinic locations and wellness centers hosted at retailers across 39 states. The segment’s services include diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene and wellness checks. The Rx pet medications products include flea and tick control, heartworm preventatives, arthritis, thyroid, and other specialty medications.

  • Revenue in USD (TTM)1.13bn
  • Net income in USD13.19m
  • Incorporated2016
  • Employees1.93k
  • Location
    PetIQ IncPetiq Llc, 230 E. Riverside Dr.EAGLE 83616United StatesUSA
  • Phone+1 (208) 939-8900
  • Fax+1 (302) 655-5049
  • Websitehttps://petiq.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SNDL Inc672.61m-83.27m556.66m2.52k--0.6128--0.8276-0.3188-0.31882.573.430.59884.6333.15267,332.30-7.67-24.44-8.32-27.9425.0422.49-12.82-62.172.98--0.1125--27.63--49.83------
SIGA Technologies Inc172.96m83.97m608.78m45.007.343.637.203.521.161.162.412.351.020.586623.093,843,484.0049.5222.3456.2127.5682.0088.6548.5541.145.65--0.0029.5126.31-21.75100.76-30.57-26.67--
Revance Therapeutics Inc243.90m-283.87m609.46m597.00------2.50-3.17-3.212.64-1.240.44661.359.18408,542.70-51.97-55.55-61.40-63.2071.53---116.39-304.963.01-22.091.41--76.55128.849.10---0.3022--
Sinovac Biotech Ltd429.20m-130.73m639.90m3.04k------1.49-1.31-1.314.3186.810.03220.20191.08141,325.00-2.2336.14-3.3058.3792.0990.77-69.1965.8711.24--0.0262---69.9714.31-198.16--91.80--
Pacira Biosciences Inc690.31m63.59m677.60m711.0012.560.77054.920.98161.171.1712.3419.070.43291.836.77970,900.103.993.354.263.9874.0572.639.218.575.70--0.40130.001.2214.88163.72--0.8761--
Pliant Therapeutics Inc0.00-185.41m767.31m158.00--1.94-----3.09-3.090.006.500.00----0.00-35.03-33.24-37.15-35.39-------360.29----0.0711---83.69---30.83---16.89--
Avid Bioservices Inc142.36m-144.17m794.25m371.00--13.54--5.58-2.27-2.272.240.91920.36613.814.32383,714.30-37.08-0.826-57.59-1.206.2719.26-101.27-2.141.05-3.180.7343---6.2721.15-54,444.79--84.15--
Liquidia Corp14.84m-112.11m862.67m136.00--12.51--58.13-1.57-1.570.21020.82080.0993--4.04109,117.60-75.00-55.02-87.85-62.6969.5282.18-755.46-474.595.78-29.470.578--9.7545.23-91.40--66.93--
Phibro Animal Health Corp1.02bn2.42m907.69m1.94k376.393.5423.520.89190.05950.059525.116.341.042.596.11524,576.800.24733.930.30714.9030.8231.180.23743.771.641.760.655456.454.074.21-92.59-46.356.650.8548
PetIQ Inc1.13bn13.19m926.89m1.93k80.903.5616.460.81710.38020.380235.278.641.285.585.55586,823.101.54-4.321.96-5.2324.6320.051.21-3.661.682.090.63--19.5815.83104.42--4.96--
Evolus Inc237.26m-53.21m1.04bn304.00--53.67--4.37-0.9073-0.90734.020.30631.184.326.58869,084.30-26.42-40.92-34.63-59.7469.7265.43-22.43-80.462.67-2.000.8623--35.98--17.10--182.77--
Innoviva Inc330.50m145.42m1.23bn112.0011.901.856.643.721.651.654.1510.640.28211.023.782,950,857.0012.4126.2412.7828.5387.06--44.0076.8411.40--0.4019---6.303.53-15.99-14.57----
Collegium Pharmaceutical Inc576.65m99.89m1.25bn197.0016.955.815.152.172.302.3012.436.700.50878.143.282,927,173.008.812.7914.584.8061.9450.8817.325.161.043.690.71850.0022.1715.11292.60---54.77--
ANI Pharmaceuticals Inc538.95m22.95m1.27bn642.0050.782.7914.912.361.191.1927.9322.810.60551.813.18839,490.603.04-2.833.56-3.3561.3460.185.01-6.153.073.100.3725--53.8719.28131.250.17549.08--
Data as of Sep 19 2024. Currency figures normalised to PetIQ Inc's reporting currency: US Dollar USD

Institutional shareholders

45.64%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 20242.15m7.26%
The Vanguard Group, Inc.as of 30 Jun 20242.14m7.20%
Eos Management LPas of 30 Jun 20241.97m6.65%
Glazer Capital LLCas of 22 Aug 20241.64m5.52%
Aristotle Capital Boston LLCas of 30 Jun 20241.23m4.16%
Dimensional Fund Advisors LPas of 30 Jun 20241.16m3.92%
Boston Partners Global Investors, Inc.as of 30 Jun 20241.04m3.51%
Nepsis, Inc.as of 30 Jun 2024901.43k3.04%
Thornburg Investment Management, Inc.as of 30 Jun 2024663.29k2.24%
Geode Capital Management LLCas of 30 Jun 2024636.87k2.15%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.